Edition:
United States

Cancer Genetics Inc (CGIX.OQ)

CGIX.OQ on NASDAQ Stock Exchange Capital Market

3.45USD
4:00pm EDT
Change (% chg)

$0.15 (+4.55%)
Prev Close
$3.30
Open
$3.35
Day's High
$3.60
Day's Low
$3.35
Volume
39,755
Avg. Vol
36,115
52-wk High
$5.25
52-wk Low
$1.10

Latest Key Developments (Source: Significant Developments)

Cancer Genetics to acquire vivoPharm
Monday, 14 Aug 2017 05:01pm EDT 

Aug 14 (Reuters) - Cancer Genetics Inc -:Cancer Genetics announces transformative and accretive acquisition of vivoPharm, a global oncology & immuno-oncology discovery services company.Cancer Genetics Inc - entered into a definitive agreement for cancer genetics to acquire vivoPharm for approximately $12 million usd.Cancer Genetics Inc - Brandt will become president of discovery & early development services at CGI upon completion of acquisition.Cancer Genetics - purchase price is about$12 million, which will include usd $1.2 million in cash and remaining 90% will be shares of CGI common stock.Cancer Genetics Inc - transaction has been approved by boards of directors of both companies.Cancer Genetics Inc - acquisition is expected to be immediately accretive, adding both revenue and income.Cancer Genetics Inc - additionally on August 14, cgi entered into an equity financing arrangement for up to usd $16 million to fund acquisition.Cancer Genetics Inc - initial tranche of funding will be usd $3 million, additional tranches can be accessed by CGI at co's discretion over next 2 years.  Full Article

Cancer Genetics reports Q2 loss per share $0.16
Monday, 14 Aug 2017 04:56pm EDT 

Aug 14 (Reuters) - Cancer Genetics Inc -:Cancer Genetics Inc announces second quarter 2017 financial results, accretive acquisition and capital raise.Q2 loss per share $0.16.Q2 revenue $6.6 million versus I/B/E/S view $8 million.Q2 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.Cancer genetics inc - ‍acquiring vivopharm for total purchase price of usd $12 million, with proceeds to be 90 percent CGIX stock, and 10 percent cash​.Cancer Genetics Inc - ‍vivopharm deal expected to "immediately" add approximately $5 million revenue.  Full Article

DIA elects Cancer Genetics Inc's John A. (Jay) Roberts as Chairman of board
Thursday, 3 Aug 2017 07:30am EDT 

Aug 3 (Reuters) - Cancer Genetics Inc ::DIA elects Cancer Genetics Inc's John A(Jay) Roberts as chairman of DIA board of directors.Cancer Genetics Inc - ‍elected John A (Jay) Roberts as chairman of board of directors for one-year term of 2017 - 2018.​.  Full Article

Cancer Genetics files for mixed shelf of up to $100 mln
Thursday, 25 May 2017 04:06pm EDT 

May 25 (Reuters) - Cancer Genetics Inc :Cancer Genetics inc files for mixed shelf of up to $100 million - sec filing.  Full Article

Cancer Genetics partners with Ventana Medical Systems for market access to predictive biomarker test
Monday, 15 May 2017 07:00am EDT 

May 15 (Reuters) - Cancer Genetics Inc :Cancer Genetics, Inc. Partners with Ventana Medical Systems, Inc., a member of the Roche Group, to ensure market access to predictive biomarker test for new immuno-oncology (io) therapy for advanced bladder cancer.Cancer Genetics - partnered with Ventana Medical Systems to enable rapid patient access to testing following FDA's approval of Roche's Ventana PD-l1 assay.  Full Article

CANCER GENETICS INC REPORTS Q1 LOSS PER SHARE $0.51
Thursday, 11 May 2017 06:23pm EDT 

May 11 (Reuters) - Cancer Genetics Inc :CANCER GENETICS INC ANNOUNCES 15% REVENUE INCREASE IN FIRST QUARTER OF 2017 OVER 2016 ON STRONG ORGANIC GROWTH WHILE CONTINUING ON PATH TO PROFITABILITY.Q1 LOSS PER SHARE $0.51.Q1 REVENUE ROSE 15 PERCENT TO $7.0 MILLION.Q1 ADJUSTED LOSS PER SHARE $0.11.  Full Article

Cancer Genetics and Mendel.ai announce strategic partnership
Monday, 3 Apr 2017 07:00am EDT 

Cancer Genetics Inc : Cancer Genetics, Inc. and Mendel.ai announce strategic partnership enabling artificial intelligence in precision medicine to drive personalized treatment and accelerate clinical trial matching for cancer care .Cancer Genetics - expect that initial partners will be using Mendel.ai system during Q2 of 2017 with wider rollout through Q3 and Q4 of this year.  Full Article

Cancer Genetic Q4 loss per share $0.15
Thursday, 23 Mar 2017 07:30am EDT 

Cancer Genetics Inc : Cancer Genetics, Inc. Announces record revenue for fourth quarter and full-year 2016 and provides 2017 business update . Q4 loss per share $0.15 .Q4 revenue rose 32 percent to $7.2 million.  Full Article

Cancer Genetics selected by BeiGene to collaborate on clinical trial services, advance portfolio of Novel Oncology Therapeutics
Wednesday, 7 Dec 2016 07:54am EST 

Cancer Genetics Inc :Cancer Genetics, Inc is selected by BeiGene, Ltd to collaborate on clinical trial services & advance portfolio of Novel Oncology Therapeutics.  Full Article

Cancer Genetics receives New York state approval for Focus::Myeloid NGS-based panel
Wednesday, 17 Aug 2016 07:30am EDT 

Cancer Genetics Inc :Received New York state approval for its Focus::Myeloid NGS-based panel for Myeloid malignancies.  Full Article

BRIEF-Cancer Genetics to acquire vivoPharm

* Cancer Genetics announces transformative and accretive acquisition of vivoPharm, a global oncology & immuno-oncology discovery services company